This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hole, A. Articles by Quadir, S. Search for Related Content PubMed Articles by Hole, A. Articles by Quadir, S. Social Bookmarking                         What's this?

Audit of efficacy of 3 mg versus 1 mg of intravenous granisetron as antiemetic prophylaxis against acute emesis caused by cisplatin or melphalan

Pharmacy Department, Royal Marsden National Health Service Trust, Sutton, Surrey, United Kingdom

Alison Conway, MSc, MRPharmS

Pharmacy Department, Royal Marsden National Health Service Trust, Sutton, Surrey, United Kingdom

Suraya Quadir, MSc, MRPharmS

Pharmacy Department, Royal Marsden National Health Service Trust, Sutton, Surrey, United Kingdom

Objective. In the United Kingdom, granisetron is licensed at an adult dose of 3 mg for prophylaxis of emesis due to cytotoxic chemotherapy. In the United States, however, the licensed dose is 10 mg/kg, which, for most adults, equates to 1 mg. In view of the cost implications of this difference in dosage recommendations, the local drug and therapeutics advisory committee supported a proposal to evaluate the use of the 1-mg dose for our own patients. We report the results of this evaluation in patients receiving the highly emetic drugs cisplatin and melphalan, given alone or in combination with other cytotoxics.

Design. Prospective, open, non-randomised study of patients receiving 3 mg and 1 mg of granisetron as part of their antiemetic regimen. Data collection was carried out before and after a change in hospital antiemetic policy.

Setting. A specialist oncology hospital in England.

Patients. A total of 57 patients received 3 mg of granisetron, and 70 patients received 1 mg of granisetron.

Results. There was a small increase in the incidence of nausea and vomiting following the change in the granisetron dose from 3 mg to 1 mg, but this increase was not big enough to be significant.

Conclusion. Guidelines recommending the use of granisetron at a dose of 1 mg were successfully implemented at the Royal Marsden Hospital with the potential to save the Trust over £50,000 per year without detriment to patient care.

Key Words: Granisetron • cisplatin • melphalan • vomiting • drug therapy

Journal of Oncology Pharmacy Practice, Vol. 5, No. 4, 194-196 (1999)
DOI: 10.1177/107815529900500406


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?